IDH Mutations in Chondrosarcoma: Case Closed or Not?

Author:

Venneker Sanne1ORCID,Bovée Judith V. M. G.1ORCID

Affiliation:

1. Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

Abstract

Chondrosarcomas are malignant cartilage-producing tumours that frequently harbour isocitrate dehydrogenase 1 and -2 (IDH) gene mutations. Several studies have confirmed that these mutations are key players in the early stages of cartilage tumour development, but their role in later stages remains ambiguous. The prognostic value of IDH mutations remains unclear and preclinical studies have not identified effective treatment modalities (in)directly targeting these mutations. In contrast, the IDH mutation status is a prognostic factor in other cancers, and IDH mutant inhibitors as well as therapeutic strategies targeting the underlying vulnerabilities induced by IDH mutations seem effective in these tumour types. This discrepancy in findings might be ascribed to a difference in tumour type, elevated D-2-hydroxyglutarate levels, and the type of in vitro model (endogenous vs. genetically modified) used in preclinical studies. Moreover, recent studies suggest that the (epi)genetic landscape in which the IDH mutation functions is an important factor to consider when investigating potential therapeutic strategies or patient outcomes. These findings imply that the dichotomy between IDH wildtype and mutant is too simplistic and additional subgroups indeed exist within chondrosarcoma. Future studies should focus on the identification, characterisation, and tailoring of treatments towards these biological subgroups within IDH wildtype and mutant chondrosarcoma.

Funder

Netherlands Organization for Scientific Research

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference89 articles.

1. WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours—Soft Tissue and Bone Tumours, IARC Press.

2. WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours—Soft Tissue and Bone Tumours, IARC Press.

3. WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours—Soft Tissue and Bone Tumours, IARC Press.

4. WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours—Soft Tissue and Bone Tumours, IARC Press.

5. WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours—Soft Tissue and Bone Tumours, IARC Press.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3